Analysts’ Viewpoint
Increase in prevalence of pneumonia, advancements in testing technologies, and growth in awareness about the importance of early diagnosis and treatment are some of the key pneumonia testing market drivers. Demand for pneumonia testing is rising owing to the growth in incidence of respiratory infections, particularly in elderly and immunocompromised populations. This is likely to augment pneumonia testing market dynamics in the near future.
Leading players are focusing on developing new, more accurate, and efficient testing technologies for pneumonia, such as polymerase chain reaction (PCR) and loop-mediated isothermal amplification (LAMP). This is creating lucrative pneumonia testing market opportunities for key players. However, high cost of some of the advanced pneumonia tests in lower-income countries is projected to hamper market statistics during the forecast period.
Pneumonia testing refers to medical tests used to diagnose pneumonia, a lung infection that causes inflammation in one or both lungs. In some cases, a physician may also order a chest CT scan or a bronchoscopy. The specific tests used for pneumonia diagnosis depend on various factors such as a patient's age, medical history, and symptoms.
Various types of pneumonia testing methods are available in the market. These include chest X-rays, sputum test, blood tests, and rapid antigen test. Increase in adoption of home-based testing and telemedicine is expected to boost pneumonia testing market growth in the near future.
Rise in incidence of pneumonia has resulted in growth in need for accurate and timely diagnosis of the disease. This is driving the demand for pneumonia testing, which helps in identifying the causative agent of the disease and providing appropriate treatment. The elderly population is more susceptible to pneumonia and other respiratory infections.
Pneumonia is one of the leading causes of death worldwide. According to The Centers for Disease Control and Prevention (CDC), pneumonia caused more than 50,000 deaths in the U.S. in 2019. As per the World Health Organization (WHO), pneumonia is a significant global health issue, especially for children under five years of age. In 2019, it was responsible for 14.0% of all deaths in children under five and 22.0% of all deaths in children aged one to five years, resulting in 740,180 deaths worldwide.
Development of new and more sensitive and specific testing methods is augmenting the global pneumonia testing business. The need for rapid and accurate test results has become increasingly important owing the rise in outbreak of pandemics. Rapid diagnostic tests, such as rapid antigen tests, can provide results in just a few minutes, allowing healthcare providers to quickly diagnose and treat patients with pneumonia.
Molecular diagnostic techniques, such as PCR, provide highly accurate results. These techniques are particularly important in detecting antibiotic-resistant strains of pneumonia. Pneumonia is a major global health concern, particularly in developing countries where access to healthcare is limited. Therefore, development of new testing methods is likely to help address this challenge, as early and accurate diagnosis is key to better patient outcomes.
Government agencies are allocating funds to support research and development of new and innovative diagnostic techniques for pneumonia. This is leading to the development of more accurate and efficient tests for pneumonia. Governments are investing in building and expanding healthcare infrastructure, including setting up of diagnostic centers and hospitals. This increased access to healthcare facilities is ultimately fueling the demand for pneumonia testing.
Governments of various countries are implementing policies that mandate the testing of individuals for pneumonia, particularly in high-risk populations such as the elderly, young children, and individuals with underlying health conditions. Several governments are providing subsidies and incentives to healthcare providers and manufacturers to encourage them to develop more affordable pneumonia testing solutions. This is likely to help make testing more accessible to a larger section of the population.
As per the pneumonia testing market research report, the bacterial type segment is anticipated to hold major share of the global market during the forecast period.
Pneumonia is often caused by bacterial infections, such as streptococcus pneumoniae and haemophilus influenzae. The bacterial type of pneumonia can be diagnosed through laboratory tests, such as cultures or antigen detection tests, which can accurately identify the specific type of bacterium causing the infection.
Bacterial pneumonia is a common form of pneumonia. Early and accurate diagnosis is crucial in choosing the appropriate treatment. Tests for bacterial pneumonia have high sensitivity and specificity, making them a reliable option for detecting the presence of bacterial infections.
According to the global pneumonia testing market forecast report, North America is projected to dominate the global landscape during the forecast period. The pneumonia testing market size in the region is estimated to increase during the forecast period, owing to the high incidence of pneumonia in countries such as the U.S. and growth in awareness about early-stage stage diagnosis and testing.
North America has a well-established medical infrastructure, with advanced laboratory facilities and highly trained medical professionals. It also has strong regulatory support for medical technology, including pneumonia testing. This helps ensure the quality and accuracy of tests and encourages investment in research and development.
As per the pneumonia testing market analysis report, the market in Asia Pacific is growing at a rapid pace due to several factors such as increase in incidence of pneumonia, rise in elderly population, and presence of various governmental initiatives to raise awareness about pneumonia. Growth in healthcare expenditure and development of new and advanced diagnostic technologies are also boosting pneumonia testing market development in Asia Pacific.
High incidence of pneumonia, advanced healthcare infrastructure, presence of several leading players, and rise in awareness about the importance of early diagnosis and treatment are some of the factors contributing to market growth in Europe.
Large numbers of players, from large multinational corporations to small, niche companies, operate in the global pneumonia testing market. New entrants and existing players are constantly developing and launching new and innovative products to gain an edge in this highly competitive market.
BD (Becton, Dickinson and Company), F. Hoffmann-La Roche Ltd., Abbott, Siemens Healthcare GmbH, Thermo Fisher Scientific Inc., BIOMÉRIEUX, Danaher, Hologic, Inc., Quidel Corporation, QIAGEN, Cepheid, Hologic, Inc., Luminex Corporation, and Bio-Rad Laboratories, Inc. are some the key pneumonia testing market players operating across the globe. These players are engaged in mergers & acquisitions and strategic collaborations to increase their market share.
The pneumonia testing market report profiles the top players based on various parameters including company overview, financial summary, business strategies, product portfolio, business segments, and recent advancements.
|
Attribute |
Detail |
|
Size in 2022 |
US$ 662.6 Mn |
|
Forecast (Value) in 2031 |
More than US$ 843.8 Mn |
|
Growth Rate (CAGR) 2023-2031 |
3.8% |
|
Forecast Period |
2023–2031 |
|
Historical Data Available for |
2017–2022 |
|
Quantitative Units |
US$ Mn for Value |
|
Market Analysis |
It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis. |
|
Competition Landscape |
|
|
Format |
Electronic (PDF) + Excel |
|
Segmentation |
|
|
Regions Covered |
|
|
Countries Covered |
|
|
Companies Profiled |
|
|
Customization Scope |
Available upon request |
|
Pricing |
Available upon request |
It was valued at US$ 662.6 Mn in 2022
It is projected to reach more than US$ 843.8 Mn by 2031
The CAGR is anticipated to be 3.8% from 2023 to 2031
The bacterial segment accounted for more than 60.0% share in 2022
North America is likely to account for the largest share during the forecast period
BD (Becton, Dickinson and Company), F. Hoffmann-La Roche Ltd., Abbott, Siemens Healthcare GmbH, Thermo Fisher Scientific Inc., BIOMÉRIEUX, Danaher, Hologic, Inc., Quidel Corporation, QIAGEN, Cepheid, Luminex Corporation, and Bio-Rad Laboratories, Inc.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Pneumonia Testing Market
4. Market Overview
4.1. Introduction
4.1.1. Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Pneumonia Testing Market Analysis and Forecast, 2017 - 2031
4.4.1. Market Revenue Projections (US$ Mn)
4.5. Porter’s Five Force Analysis
5. Key Insights
5.1. Overview of Pneumonia (Causes, Symptoms and Treatment)
5.2. Disease Prevalence & Incidence Rate globally with key countries
5.3. Brief about the Diagnosis/Testing of Pneumonia
5.4. COVID 19 Impact on Industry
6. Global Pneumonia Testing Market Analysis and Forecast, By Test Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast By Test Type, 2017 - 2031
6.3.1. Blood Test
6.3.2. Imaging Test
6.3.3. Sputum Test
6.3.4. Urine Test
6.3.5. Others
6.4. Market Attractiveness By Test Type
7. Global Pneumonia Testing Market Analysis and Forecast, By Type
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast By Type, 2017 - 2031
7.3.1. Bacterial
7.3.1.1. Streptococcus
7.3.1.2. Legionella
7.3.1.3. Chlamydophila
7.3.1.4. Mycoplasma Pneumoniae
7.3.2. Viral
7.3.3. Others
7.4. Market Attractiveness By Type
8. Global Pneumonia Testing Market Analysis and Forecast, By End-user
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast By End-user, 2017 - 2031
8.3.1. Hospitals & Clinics
8.3.2. Diagnostic Laboratories
8.3.3. Others
8.4. Market Attractiveness By End-user
9. Global Pneumonia Testing Market Analysis and Forecast, By Region
9.1. Key Findings
9.2. Market Value Forecast By Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness By Country/Region
10. North America Pneumonia Testing Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast By Test Type, 2017 - 2031
10.2.1. Blood Test
10.2.2. Imaging Test
10.2.3. Sputum Test
10.2.4. Urine Test
10.2.5. Others
10.3. Market Value Forecast By Type, 2017 - 2031
10.3.1. Bacterial
10.3.1.1. Streptococcus
10.3.1.2. Legionella
10.3.1.3. Chlamydophila
10.3.1.4. Mycoplasma Pneumoniae
10.3.2. Viral
10.3.3. Others
10.4. Market Value Forecast By End-user, 2017 - 2031
10.4.1. Hospitals & Clinics
10.4.2. Diagnostic Laboratories
10.4.3. Others
10.5. Market Value Forecast By Country, 2017 - 2031
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Test Type
10.6.2. By Type
10.6.3. By End-user
10.6.4. By Country
11. Europe Pneumonia Testing Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast By Test Type, 2017 - 2031
11.2.1. Blood Test
11.2.2. Imaging Test
11.2.3. Sputum Test
11.2.4. Urine Test
11.2.5. Others
11.3. Market Value Forecast By Type, 2017 - 2031
11.3.1. Bacterial
11.3.1.1. Streptococcus
11.3.1.2. Legionella
11.3.1.3. Chlamydophila
11.3.1.4. Mycoplasma Pneumoniae
11.3.2. Viral
11.3.3. Others
11.4. Market Value Forecast By End-user, 2017 - 2031
11.4.1. Hospitals & Clinics
11.4.2. Diagnostic Laboratories
11.4.3. Others
11.5. Market Value Forecast By Country, 2017 - 2031
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Spain
11.5.5. Italy
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Test Type
11.6.2. By Type
11.6.3. By End-user
11.6.4. By Country
12. Asia Pacific Pneumonia Testing Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast By Test Type, 2017 - 2031
12.2.1. Blood Test
12.2.2. Imaging Test
12.2.3. Sputum Test
12.2.4. Urine Test
12.2.5. Others
12.3. Market Value Forecast By Type, 2017 - 2031
12.3.1. Bacterial
12.3.1.1. Streptococcus
12.3.1.2. Legionella
12.3.1.3. Chlamydophila
12.3.1.4. Mycoplasma Pneumoniae
12.3.2. Viral
12.3.3. Others
12.4. Market Value Forecast By End-user, 2017 - 2031
12.4.1. Hospitals & Clinics
12.4.2. Diagnostic Laboratories
12.4.3. Others
12.5. Market Value Forecast By Country, 2017 - 2031
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Test Type
12.6.2. By Type
12.6.3. By End-user
12.6.4. By Country
13. Latin America Pneumonia Testing Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast By Test Type, 2017 - 2031
13.2.1. Blood Test
13.2.2. Imaging Test
13.2.3. Sputum Test
13.2.4. Urine Test
13.2.5. Others
13.3. Market Value Forecast By Type, 2017 - 2031
13.3.1. Bacterial
13.3.1.1. Streptococcus
13.3.1.2. Legionella
13.3.1.3. Chlamydophila
13.3.1.4. Mycoplasma Pneumoniae
13.3.2. Viral
13.3.3. Others
13.4. Market Value Forecast By End-user, 2017 - 2031
13.4.1. Hospitals & Clinics
13.4.2. Diagnostic Laboratories
13.4.3. Others
13.5. Market Value Forecast By Country, 2017 - 2031
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
13.6.1. By Test Type
13.6.2. By Type
13.6.3. By End-user
13.6.4. By Country
14. Middle East & Africa Pneumonia Testing Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast By Test Type, 2017 - 2031
14.2.1. Blood Test
14.2.2. Imaging Test
14.2.3. Sputum Test
14.2.4. Urine Test
14.2.5. Others
14.3. Market Value Forecast By Type, 2017 - 2031
14.3.1. Bacterial
14.3.1.1. Streptococcus
14.3.1.2. Legionella
14.3.1.3. Chlamydophila
14.3.1.4. Mycoplasma Pneumoniae
14.3.2. Viral
14.3.3. Others
14.4. Market Value Forecast By End-user, 2017 - 2031
14.4.1. Hospitals & Clinics
14.4.2. Diagnostic Laboratories
14.4.3. Others
14.5. Market Value Forecast By Country, 2017 - 2031
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
14.6.1. By Test Type
14.6.2. By Type
14.6.3. By End-user
14.6.4. By Country
15. Competition Landscape
15.1. Market Player – Competition Matrix (By Tier and Size of companies)
15.2. Market Share Analysis By Company (2022)
15.3. Company Profiles
15.3.1. BD (Becton, Dickinson and Company)
15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.1.2. Product Portfolio
15.3.1.3. Financial Overview
15.3.1.4. SWOT Analysis
15.3.1.5. Strategic Overview
15.3.2. F. Hoffmann-La Roche Ltd.
15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.2.2. Product Portfolio
15.3.2.3. Financial Overview
15.3.2.4. SWOT Analysis
15.3.2.5. Strategic Overview
15.3.3. Abbott
15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.3.2. Product Portfolio
15.3.3.3. Financial Overview
15.3.3.4. SWOT Analysis
15.3.3.5. Strategic Overview
15.3.4. Siemens Healthcare GmbH
15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.4.2. Product Portfolio
15.3.4.3. Financial Overview
15.3.4.4. SWOT Analysis
15.3.4.5. Strategic Overview
15.3.5. Thermo Fisher Scientific Inc.
15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.5.2. Product Portfolio
15.3.5.3. Financial Overview
15.3.5.4. SWOT Analysis
15.3.5.5. Strategic Overview
15.3.6. BIOMÉRIEUX
15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.6.2. Product Portfolio
15.3.6.3. Financial Overview
15.3.6.4. SWOT Analysis
15.3.6.5. Strategic Overview
15.3.7. Danaher
15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.7.2. Product Portfolio
15.3.7.3. Financial Overview
15.3.7.4. SWOT Analysis
15.3.7.5. Strategic Overview
15.3.8. Hologic, Inc.
15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.8.2. Product Portfolio
15.3.8.3. Financial Overview
15.3.8.4. SWOT Analysis
15.3.8.5. Strategic Overview
15.3.9. Quidel Corporation
15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.9.2. Product Portfolio
15.3.9.3. Financial Overview
15.3.9.4. SWOT Analysis
15.3.9.5. Strategic Overview
15.3.10. QIAGEN
15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.10.2. Product Portfolio
15.3.10.3. Financial Overview
15.3.10.4. SWOT Analysis
15.3.10.5. Strategic Overview
15.3.11. Cepheid
15.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.11.2. Product Portfolio
15.3.11.3. Financial Overview
15.3.11.4. SWOT Analysis
15.3.11.5. Strategic Overview
15.3.12. Hologic, Inc.
15.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.12.2. Product Portfolio
15.3.12.3. Financial Overview
15.3.12.4. SWOT Analysis
15.3.12.5. Strategic Overview
15.3.13. Luminex Corporation
15.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.13.2. Product Portfolio
15.3.13.3. Financial Overview
15.3.13.4. SWOT Analysis
15.3.13.5. Strategic Overview
15.3.14. Bio-Rad Laboratories, Inc.
15.3.14.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.14.2. Product Portfolio
15.3.14.3. Financial Overview
15.3.14.4. SWOT Analysis
15.3.14.5. Strategic Overview
List of Tables
Table 01: Global Pneumonia Testing Market Value (US$ Mn) Forecast, by Test Type, 2017–2031
Table 02: Global Pneumonia Testing Market Value (US$ Mn) Forecast, by Type, 2017–2031
Table 03: Global Pneumonia Testing Market Value (US$ Mn) Forecast, By End-user, 2017–2031
Table 04: Global Pneumonia Testing Market Value (US$ Mn) Forecast, by Region, 2017–2031
Table 05: North America Pneumonia Testing Market Value (US$ Mn) Forecast, by Test Type, 2017–2031
Table 06: North America Pneumonia Testing Market Value (US$ Mn) Forecast, by Type, 2017–2031
Table 07: North America Pneumonia Testing Market Value (US$ Mn) Forecast, By End-user, 2017–2031
Table 08: North America Pneumonia Testing Market Value (US$ Mn) Forecast, by Country, 2017–2031
Table 09: Europe Pneumonia Testing Market Value (US$ Mn) Forecast, by Test Type, 2017–2031
Table 10: Europe Pneumonia Testing Market Value (US$ Mn) Forecast, by Type, 2017–2031
Table 11: Europe Pneumonia Testing Market Value (US$ Mn) Forecast, By End-user, 2017–2031
Table 12: Europe Pneumonia Testing Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 13: Asia Pacific Pneumonia Testing Market Value (US$ Mn) Forecast, by Test Type, 2017–2031
Table 14: Asia Pacific Pneumonia Testing Market Value (US$ Mn) Forecast, by Type, 2017–2031
Table 15: Asia Pacific Pneumonia Testing Market Value (US$ Mn) Forecast, By End-user, 2017–2031
Table 16: Asia Pacific Pneumonia Testing Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 17: Latin America Pneumonia Testing Market Value (US$ Mn) Forecast, by Test Type, 2017–2031
Table 18: Latin America Pneumonia Testing Market Value (US$ Mn) Forecast, by Type, 2017–2031
Table 19: Latin America Pneumonia Testing Market Value (US$ Mn) Forecast, By End-user, 2017–2031
Table 20: Latin America Pneumonia Testing Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 21: Middle East & Africa Pneumonia Testing Market Value (US$ Mn) Forecast, by Test Type, 2017–2031
Table 22: Middle East & Africa Pneumonia Testing Market Value (US$ Mn) Forecast, by Type, 2017–2031
Table 23: Middle East & Africa Pneumonia Testing Market Value (US$ Mn) Forecast, By End-user, 2017–2031
Table 24: Middle East & Africa Pneumonia Testing Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
List of Figures
Figure 01: Global Pneumonia Testing Market Value (US$ Mn) Forecast, 2017–2031
Figure 02: Global Pneumonia Testing Market Value Share Analysis, by Test Type, 2022 and 2031
Figure 03: Global Pneumonia Testing Market Attractiveness Analysis, by Test Type, 2023–2031
Figure 04: Global Pneumonia Testing Market Value Share Analysis, by Type, 2022 and 2031
Figure 05: Global Pneumonia Testing Market Attractiveness Analysis, by Type, 2023–2031
Figure 06: Global Pneumonia Testing Market Value Share Analysis, By End-user, 2022 and 2031
Figure 07: Global Pneumonia Testing Market Attractiveness Analysis, By End-user, 2023–2031
Figure 08: Global Pneumonia Testing Market Value Share Analysis, by Region, 2022 and 2031
Figure 09: Global Pneumonia Testing Market Attractiveness Analysis, by Region, 2023–2031
Figure 10: North America Pneumonia Testing Market Value (US$ Mn) Forecast, 2017–2031
Figure 11: North America Pneumonia Testing Market Value Share Analysis, by Test Type, 2022 and 2031
Figure 12: North America Pneumonia Testing Market Attractiveness Analysis, by Test Type, 2023–2031
Figure 13: North America Pneumonia Testing Market Value Share Analysis, by Type, 2022 and 2031
Figure 14: North America Pneumonia Testing Market Attractiveness Analysis, by Type, 2023–2031
Figure 15: North America Pneumonia Testing Market Value Share Analysis, By End-user, 2022 and 2031
Figure 16: North America Pneumonia Testing Market Attractiveness Analysis, By End-user, 2023–2031
Figure 17: North America Pneumonia Testing Market Value Share Analysis, by Country, 2022 and 2031
Figure 18: North America Pneumonia Testing Market Attractiveness Analysis, by Country, 2023–2031
Figure 19: Europe Pneumonia Testing Market Value (US$ Mn) Forecast, 2017–2031
Figure 20: Europe Pneumonia Testing Market Value Share Analysis, by Test Type, 2022 and 2031
Figure 21: Europe Pneumonia Testing Market Attractiveness Analysis, by Test Type, 2023–2031
Figure 22: Europe Pneumonia Testing Market Value Share Analysis, by Type, 2022 and 2031
Figure 23: Europe Pneumonia Testing Market Attractiveness Analysis, by Type, 2023–2031
Figure 24: Europe Pneumonia Testing Market Value Share Analysis, By End-user, 2022 and 2031
Figure 25: Europe Pneumonia Testing Market Attractiveness Analysis, By End-user, 2023–2031
Figure 26: Europe Pneumonia Testing Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 27: Europe Pneumonia Testing Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 28: Asia Pacific Pneumonia Testing Market Value (US$ Mn) Forecast, 2017–2031
Figure 29: Asia Pacific Pneumonia Testing Market Value Share Analysis, by Test Type, 2022 and 2031
Figure 30: Asia Pacific Pneumonia Testing Market Attractiveness Analysis, by Test Type, 2023–2031
Figure 31: Asia Pacific Pneumonia Testing Market Value Share Analysis, by Type, 2022 and 2031
Figure 32: Asia Pacific Pneumonia Testing Market Attractiveness Analysis, by Type, 2023–2031
Figure 33: Asia Pacific Pneumonia Testing Market Value Share Analysis, By End-user, 2022 and 2031
Figure 34: Asia Pacific Pneumonia Testing Market Attractiveness Analysis, By End-user, 2023–2031
Figure 35: Asia Pacific Pneumonia Testing Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 36: Asia Pacific Pneumonia Testing Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 37: Latin America Pneumonia Testing Market Value (US$ Mn) Forecast, 2017–2031
Figure 38: Latin America Pneumonia Testing Market Value Share Analysis, by Test Type, 2022 and 2031
Figure 39: Latin America Pneumonia Testing Market Attractiveness Analysis, by Test Type, 2023–2031
Figure 40: Latin America Pneumonia Testing Market Value Share Analysis, by Type, 2022 and 2031
Figure 41: Latin America Pneumonia Testing Market Attractiveness Analysis, by Type, 2023–2031
Figure 42: Latin America Pneumonia Testing Market Value Share Analysis, By End-user, 2022 and 2031
Figure 43: Latin America Pneumonia Testing Market Attractiveness Analysis, By End-user, 2023–2031
Figure 44: Latin America Pneumonia Testing Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 45: Latin America Pneumonia Testing Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 46: Middle East & Africa Pneumonia Testing Market Value (US$ Mn) Forecast, 2017–2031
Figure 47: Middle East & Africa Pneumonia Testing Market Value Share Analysis, by Test Type, 2022 and 2031
Figure 48: Middle East & Africa Pneumonia Testing Market Attractiveness Analysis, by Test Type, 2023–2031
Figure 49: Middle East & Africa Pneumonia Testing Market Value Share Analysis, by Type, 2022 and 2031
Figure 50: Middle East & Africa Pneumonia Testing Market Attractiveness Analysis, by Type, 2023–2031
Figure 51: Middle East & Africa Pneumonia Testing Market Value Share Analysis, By End-user, 2022 and 2031
Figure 52: Middle East & Africa Pneumonia Testing Market Attractiveness Analysis, By End-user, 2023–2031
Figure 53: Middle East & Africa Pneumonia Testing Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 54: Middle East & Africa Pneumonia Testing Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 55: Global Pneumonia Testing Market Share Analysis, by Company, 2022
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Pneumonia Testing Market
*86 figures and 60 tables includes